---
title: "PRP Vs BMAC Vs Adipose: Comparing Orthobiologics"
description: "How PRP, bone marrow aspirate concentrate and adipose derived preparations differ in source, processing, handling and the regulatory framing around them."
url: "https://regenmedacademy.com/prp-vs-bmac-vs-adipose-comparing-treatments/"
---

# PRP vs. BMAC vs. adipose: comparing orthobiologic treatment options

- [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/)
- June 19, 2026

![Three labeled syringes comparing prp, bmac and adipose preparations side by side on a clinical surface](https://regenmedacademy.com/wp-content/uploads/2026/09/PRP-vs.-BMAC-vs.-adipose_-comparing-orthobiologic-treatment-options-r3.webp)

*Written by [Oscar Tellez](https://regenmedacademy.com/oscar-tellez/), founder of Regen Med Academy. Oscar is not a clinician. This post is education for licensed providers and is not medical advice. Last updated November 4, 2026.*

Autologous orthobiologics have moved from a single-modality conversation to a comparison-driven one. Clinicians routinely choose between platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived products for the same patient and the same joint. The choice matters, because these three modalities differ in source tissue, cellular composition, regulatory pathway, invasiveness, evidence base, and cost. This guide walks through the comparison in a way that helps clinicians match modality to indication rather than fit every patient to a single tool.

**In short:** PRP, BMAC, and adipose-derived products are three autologous orthobiologics, and they are not interchangeable. PRP is the least invasive of the three to harvest and usually the lowest-cost option. BMAC and adipose-derived products contain mesenchymal-type cells in addition to growth factors, are more invasive to harvest, and are more expensive. All three are used off-label for musculoskeletal injection, and none is FDA approved to treat a musculoskeletal condition. Coverage depends on the plan, so check each patient’s policy before you quote a price. Head-to-head data are limited, no single modality has been shown to be “best,” and the [2026 ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf) strongly recommends against PRP and stem cell injections for knee and hip osteoarthritis. The right choice depends on indication, patient factors, clinician training, and regulatory framing. Individual results vary.

**Important Disclaimer**

Regenerative Medicine Academy (RMA) is an education company providing training for licensed clinicians. This article is educational content only and does not constitute medical, legal, business, tax, or financial advice, nor a guarantee of clinical or financial outcomes. Platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived products are subject to FDA regulation, state scope-of-practice rules, and professional society standards. All three are used off-label for musculoskeletal injection, and none is FDA approved to treat a musculoskeletal condition; enzymatically digested stromal vascular fraction (SVF) is considered a drug by the FDA and requires pre-market approval. Clinicians are responsible for verifying FDA device and biologic status, state scope-of-practice requirements, informed consent obligations, malpractice coverage, corporate-practice-of-medicine rules, and applicable advertising laws (FDA, FTC, and state) before performing any orthobiologic procedure. Comparative clinical and outcome data are heterogeneous; individual results vary. Consult qualified legal, compliance, and medical professionals before acting.

Here is what I hear from providers: “When a doctor calls me, the first thing they ask is, are stem cells legal or illegal?” For PRP, bone marrow and fat, the first answer is that these are three different products under different rules. Here is what I tell providers: “Stem cells are a category, not a product.” RMA teaches two of the three, PRP and adipose harvest, in private, hands-on training. We do not teach bone marrow aspiration or SVF preparation, so this post covers them as education only.

Think of PRP, BMAC, and adipose-derived products as three different products, each with its own harvest, evidence, and regulatory status. When a practice offers only one, its recommendation can reflect its menu rather than the evidence. When a practice markets “stem cell therapy” as a label that covers everything from plasma to fat, the result is blurred consent and regulatory exposure.

This guide walks through the comparison: the vocabulary, the biology, the harvesting and processing differences, the regulatory framing, the published evidence, patient selection, cost, safety, and the training implications. The thread running through it is simple: match the modality to the patient, match the language to the regulation, and do not collapse these three products into a single story.

## **Vocabulary discipline: what these words actually mean**

Before any comparison, the terms need to be clean. The research and regulatory worlds draw sharp lines here, and marketing language often blurs them in ways that create problems later.

Platelet-rich plasma is a concentrated platelet preparation from autologous whole blood. It contains growth factors from platelets and from the plasma. PRP does not contain nucleated stem cells.

Bone marrow aspirate concentrate is the product produced when bone marrow aspirate, usually drawn from the iliac crest, is concentrated by centrifugation. The resulting concentrate contains platelets and growth factors, a population of mesenchymal stromal cells (often abbreviated as MSCs), hematopoietic stem cells, and a variety of other nucleated cells and cytokines. The MSC concentration in bone marrow aspirate is a very small fraction of total cells to begin with, so concentration is the point of BMAC processing.

Adipose-derived products span a gradient. Autologous fat graft is fat moved from one site to another in the same patient. Microfat and nanofat are mechanically processed adipose preparations used mostly in aesthetic applications. Microfragmented adipose tissue, or MFAT, is fat that has been broken down into smaller clusters through a closed-system mechanical device without enzymes. Stromal vascular fraction, or SVF, is an enzymatically or mechanically prepared cell-rich fraction containing adipose-derived stem cells (ADSCs). Culture-expanded ADSCs are a purified, expanded cell product.

Clinicians sometimes use “stem cell therapy” as a generic label for any of these products. That habit is both clinically imprecise and regulatorily risky. PRP has no stem cells. BMAC has MSCs at low concentration. MFAT contains ADSCs within preserved perivascular niches. SVF is a cell-rich fraction. Each of these sits in a different FDA regulatory box, and conflating them is one of the most common marketing mistakes in this field.

**What this means in practice:** use the specific term for the specific product. “PRP,” “BMAC,” “MFAT,” and “SVF” are not interchangeable, and collapsing them into “stem cell therapy” will attract attention from regulators who pay very close attention to how these products are described.

## **Comparative biology, in plain language**

The three modalities differ at every level: source tissue, cellular composition, and typical delivery volume. The table below summarizes the practical differences.

Property PRP BMAC MFAT and adipose-derived

Source tissue Peripheral blood Bone marrow (usually iliac crest) Subcutaneous fat

Stem cells present None; platelets and growth factors only Mesenchymal stromal cells at low percentage of total marrow cells Adipose-derived stem cells within preserved perivascular niche

Typical injection volume Small, often in the range of several milliliters Moderate, often larger than PRP and usually in the tens of milliliters Variable, typically moderate

Activation often used Sometimes, with calcium chloride or in-situ collagen Generally not added Generally not added

One marketing claim appears often in industry literature: that MFAT contains many times more “stem cells” than BMAC. Be cautious with any such figure. Cell counts depend on the preparation method, the patient, and the counting method, and the clinical meaning of any count is not established. Do not compare cell counts or repeat a multiple in patient materials.

Free mini course

The FDA rules behind this field, in a short, self-paced course. It costs nothing.

[Get the free FDA course](https://regenmedacademy.com/fda-legal-foundations-of-regenerative-medicine/#free-course)

## **Harvesting and processing: the practical differences**

If biology sets the theoretical distinction between these modalities, harvesting and processing set the practical one. A clinician decides which modality to offer in part based on what they can safely and reproducibly perform in their setting.

PRP harvest is the least invasive. A peripheral blood draw is processed by single or double centrifugation to produce a platelet concentrate. Operator skill for the draw and spin is relatively low, though accuracy at the injection site matters, and image-guided needle placement is a skill of its own. Most of the visit goes to intake, the draw, processing, and education rather than the injection itself.

BMAC harvest is moderately invasive. Bone marrow is usually drawn from the posterior iliac crest and concentrated by centrifugation. How much to draw at each site, whether to aspirate at one level or several, and which concentration system to use are not settled questions, and this post does not try to settle them. RMA does not teach bone marrow aspiration, so the technique is outside what we cover here. Operator skill is moderate to high because bone aspiration anatomy and needle handling are not forgiving of imprecision.

Adipose harvest is moderately invasive and uses a different skill set entirely. Under tumescent anesthesia, adipose tissue is aspirated from the abdomen, flanks, thighs, or similar donor site. Harvest volume varies by system and protocol. Processing depends on the intended product: decantation and washing for simple fat grafting, centrifugation for Coleman structural grafts, mechanical emulsification for nanofat, or a closed-system device for MFAT. FDA regards SVF made by enzymatic digestion as a drug, so it cannot be given to patients outside an investigational new drug application (IND) that is in effect. Operator skill is high because liposuction technique, tumescent pharmacology, and processing system competence all have to come together.

The table below summarizes the operational comparison.

Step PRP BMAC Adipose and MFAT

Donor site Antecubital vein Posterior iliac crest most common Abdomen, flanks, thighs

Anesthesia Topical plus venipuncture Local; conscious sedation often used Tumescent local anesthesia

Invasiveness Lowest Moderate Moderate

Processing Single or double centrifugation Centrifugation; method varies by system Mechanical fragmentation, decantation, or centrifugation

Operator skill required Low to moderate Moderate to high High

## **How the regulatory framing differs**

PRP, BMAC, and adipose products are not regulated the same way, so the right language differs too. PRP preparation devices are FDA cleared for use with bone graft material: FDA classifies them as a [platelet and plasma separator for bone graft handling](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=ORG). Injecting PRP into joints, tendons, ligaments, skin or scalp is off-label. BMAC and MFAT raise a second question, because they are made from the patient’s own cells and tissue, and a device’s 510(k) clearance does not answer it.

Under [21 CFR 1271.10(a)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10), a cell or tissue product is regulated solely under section 361 of the Public Health Service Act, as tissue, if it meets all four criteria, including that it is “minimally manipulated” and “intended for homologous use only.” FDA’s [2020 guidance on minimal manipulation and homologous use](https://www.fda.gov/media/109176/download) says that using an adipose-derived product to “treat musculoskeletal conditions such as arthritis or tendonitis” by regenerating cartilage or tendon is “generally not considered a homologous use.” Bone marrow is a special case: the same guidance notes that minimally manipulated bone marrow for homologous use, not combined with another article, “is not considered an HCT/P.” Whether a given BMAC use fits those terms is a question for your regulatory counsel. The cleared indications for each BMAC or MFAT system are in its record in the [FDA 510(k) database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm), so read the record for the system you use.

Clinic-prepared enzymatic SVF is the outlier. The FDA has long treated enzymatically digested SVF as a drug, and two federal appellate courts have now ruled against clinics that offered it. In [*U.S. v. US Stem Cell Clinic* (2021)](https://media.ca11.uscourts.gov/opinions/pub/files/201913276.pdf), the Eleventh Circuit affirmed a judgment that the clinic’s SVF product was a drug and held that “the same surgical procedure exception unambiguously does not apply” to the clinic’s procedure. In [*U.S. v. California Stem Cell Treatment Center* (2024)](https://cdn.ca9.uscourts.gov/datastore/opinions/2024/09/27/22-56014.pdf), the Ninth Circuit reversed a lower court, held that the defendants’ SVF is a drug, and held that their procedure “is not exempt from regulation under the SSP exception,” meaning the same surgical procedure exception. Clinicians offering SVF outside an IND that is in effect are acting against FDA’s position and both rulings. Culture-expanded ADSCs or MSCs are also regulated as biologic drugs under Section 351 of the Public Health Service Act and are investigational only absent FDA approval. The [FDA’s patient and consumer information on regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) (content current as of April 8, 2024) is the cleanest patient-facing summary of this regulatory posture and says these therapies “have not been approved for the treatment of any orthopedic condition.”

**What this means in practice:** the language differs by product. For PRP, say the device is FDA cleared for use with bone graft material and that the injection use is off-label. For BMAC and MFAT, also say that no BMAC or adipose product is FDA approved for a musculoskeletal use, and do not let a device’s clearance stand in for the tissue question. For all three, do not imply FDA approval for a named condition, and take product status questions to your regulatory counsel.

## **What the published evidence actually says: knee osteoarthritis**

Knee osteoarthritis is the most actively studied orthobiologic indication and the best place to compare modalities with real data.

A [2021 trial by Dulic and colleagues in *Medicina*](https://www.mdpi.com/1648-9144/57/11/1193/htm) assigned 175 patients with Kellgren-Lawrence grade II to IV knee OA to BMAC, PRP, or hyaluronic acid. BMAC showed greater improvement than HA and PRP on most scores at 12 months, though not on WOMAC or the partial IKDC score against PRP, and PRP’s advantage over HA did not reach statistical significance. Allocation was uneven: 111 BMAC, 34 PRP and 30 HA. The abstract calls the trial randomized, but the methods say only the HA and PRP groups were randomly allocated, and the authors write that it “was not fully randomized.” It is a single-study signal, not a settled conclusion, and every use it tested is off-label.

A [2024 network meta-analysis by Jawanda and colleagues in *Arthroscopy*](https://pubmed.ncbi.nlm.nih.gov/38331363/) pooled 48 studies covering 9,338 knees and compared intra-articular options for knee OA at a minimum of six months of follow-up. HA and PRP improved pain compared with placebo, and HA, PRP, and BMAC all improved function compared with placebo; the abstract does not list BMAC among the injections that improved pain. The surface under the cumulative ranking curve (SUCRA) ordering placed PRP near the top, BMAC next, hyaluronic acid lower, corticosteroid below that, and placebo last. One caveat matters: the abstract lists BMAC as the least studied injection, at 2.5 percent against 21.5 percent for PRP, and does not say whether those shares count studies, knees, or treatment arms, so BMAC’s ranking rests on thin data. Network meta-analyses are a useful synthesis tool but have meaningful limitations, particularly when the underlying studies differ in preparation protocols, patient selection, and outcome measures. The practical takeaway is that this analysis found PRP improved pain and function compared with placebo, and BMAC function only, and that neither can be declared definitively superior for knee OA from the current evidence. Every one of these uses is off-label.

For hip OA, professional guidance now speaks directly. The [2026 ACR guideline update](https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf), approved by the ACR Board of Directors on September 8, 2026 and published as a summary ahead of the full papers, says: “In people with knee and hip OA, we strongly recommend against PRP treatment” and “we strongly recommend against stem cell injections.” It strongly recommends intraarticular glucocorticoid injections and conditionally recommends against intraarticular hyaluronic acid. The summary does not name BMAC or adipose products separately. No PRP, BMAC, or adipose product is FDA approved for hip OA, and every one of these uses is off-label.

For MFAT against BMAC, the evidence is thinner. A [2019 retrospective review by Mautner and colleagues in *Stem Cells Translational Medicine*](https://academic.oup.com/stcltm/article/8/11/1149/6403880) compared 76 patients (106 knees) given BMAC or MFAT for knee OA and found “not a significant difference when comparing postprocedure scores between groups.” Patients were not randomized, and there was no placebo or other comparison group, so the study cannot show that the two are equivalent or that either one caused a change. Whether MFAT and BMAC differ for knee OA is not settled, and both uses are off-label.

In the same 2024 network meta-analysis, BMAC ranked below PRP, and the abstract does not list it among the injections that improved pain, so the pooled data do not show BMAC to be better than PRP. The PRP literature is also uneven: preparations differ from one study to the next, and platelet dose is studied as one factor; no society names a minimum or a target dose. That matters because it shapes how any single trial should be interpreted: the label on the tube is not the same as the dose delivered.

Professional society guidance is a useful anchor for patients asking what “the field” recommends. The [American Academy of Orthopaedic Surgeons clinical practice guideline for management of knee osteoarthritis (nonarthroplasty)](https://www.aaos.org/quality/quality-programs/osteoarthritis-of-the-knee/) evaluates PRP and other injectable options and is a primary reference for clinicians discussing evidence strength with patients.

**What this means in practice:** when a patient asks which modality is “best” for their knee OA, say what the named sources found and where they stop. The 2024 network meta-analysis found PRP improved pain and function compared with placebo, and BMAC function only. The 2019 retrospective review found no significant difference between MFAT and BMAC groups. The 2026 ACR guideline update strongly recommends against PRP and stem cell injections for knee and hip OA. Every one of these uses is off-label, and no modality has been shown to be definitively superior.

## **Matching modality to indication: a framework, not a formula**

Even without definitive head-to-head evidence, clinicians can make reasoned choices based on the biology, invasiveness, cost, and the pattern of published results.

PRP is the least invasive of the three to harvest and usually the lowest cost. Some clinicians consider BMAC or MFAT for moderate to severe knee or hip OA, or for partial tendon tears. The sources above do not show either to be consistently better than PRP, every one of these uses is off-label, and the 2026 ACR guideline update strongly recommends against PRP and stem cell injections for knee and hip OA. Which harvest suits which patient is not settled, so make the choice on purpose, record why, and explain it in the consent conversation.

One practical overlay: each harvest has its own intake questions. Age, body mass, diabetes, prior radiation, and the full medication list all belong in planning, but how much each one matters for a given harvest is not settled, so this post does not rank them. For NSAIDs and other medication holds around PRP, there is no agreed washout period. Published protocols differ, so follow your own protocol and the prescriber, and never stop an antiplatelet drug without the prescriber. These are planning factors that shape patient selection and consent, not absolute contraindications.

## **Cost and access: what to check before you quote**

Do not assume insurance pays for any of the three for musculoskeletal use. When we checked on November 4, 2026, Medicare’s [national coverage determination 270.3](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=217), in its version effective April 13, 2021, covered autologous PRP “for the treatment of chronic non-healing diabetic wounds” for 20 weeks when the preparation device is FDA cleared for exuding cutaneous wounds. It leaves other chronic non-healing wounds to the local Medicare Administrative Contractors, and it does not address musculoskeletal use. Commercial coverage depends on the plan. Check each patient’s policy before you quote a price, and take coverage and billing questions to the payer and your biller.

Published prices show how wide the range is. A [2024 nationwide pricing study of top U.S. orthopedic hospitals by Tiao and colleagues](https://pubmed.ncbi.nlm.nih.gov/37815436/) reported PRP prices from three hundred fifty to two thousand eight hundred fifteen dollars per injection, with a median of eight hundred dollars. That range comes from those hospitals and is not a forecast for your practice, and this post cites no published range for BMAC or MFAT. Prices vary, and your own pricing should reflect your fully loaded costs, your market and honest informed financial consent.

Out-of-pocket cost matters for patient selection and conversation. A patient weighing PRP versus MFAT is weighing not just biology but a significant cost difference, so the conversation should cover the size of that difference and what the evidence does and does not show for their specific indication.

## **Safety profile, compared directly**

This post gives no adverse event rates. Each harvest adds the risks of its own procedure, and the patient should hear them before consent.

PRP has the least invasive harvest of the three. Some soreness after the injection is common, and patients should hear that before the procedure. Bruising and swelling at the draw or injection site can also occur. Any injection into a joint carries some risk of infection, and PRP is no exception.

BMAC adds the risks of a bone marrow draw from the iliac crest, including pain at the donor site, bleeding or hematoma, nerve or vessel injury, and infection. RMA does not teach bone marrow aspiration or BMAC preparation, so needle technique and its training are outside this post.

Adipose harvest carries the risks of liposuction, most notably local anesthetic systemic toxicity. Tumescent anesthesia uses dilute lidocaine that is absorbed slowly: a [2016 study of tumescent lidocaine by Klein and Jeske](https://escholarship.org/uc/item/1pq0v0fx) sampled blood for 24 hours after infiltration and describes “delayed systemic absorption.” Because absorption is delayed, monitoring under your protocol does not stop when the case ends, and the full medication list should be reviewed with the prescriber before the case. Donor-site bruising, numbness, and contour irregularity can occur, and serious complications of liposuction such as fat embolism and abdominal wall perforation belong in the consent conversation.

Across all three, using the patient’s own tissue does not remove risk. Infection, contamination during processing, and device or handling errors remain possible.

## **Training implications: what a full-modality practice looks like**

The training barrier rises with the modality. A practice offering only PRP needs venipuncture, centrifugation, and injection technique, with ultrasound skill for musculoskeletal targets. A practice adding BMAC needs bone aspiration technique, anatomic landmarking, decisions about single-level versus multi-level aspiration, and sedation considerations. A practice adding adipose-based work needs tumescent pharmacology, liposuction skill, processing system competence, and a clear understanding that enzymatic SVF cannot be offered outside an IND that is in effect and cannot be marketed as a treatment. RMA’s own courses cover the PRP and adipose parts of that progression; RMA does not teach bone marrow aspiration or SVF preparation.

So RMA teaches two of the three, PRP and adipose. Bone marrow aspiration and SVF preparation need separate training. Training gives you supervised cases and a method. It does not guarantee a clinical result. The hands-on PRP and adipose courses are listed in [RMA’s course catalog](https://regenmedacademy.com/our-courses/). Didactic foundations for biology, regulation, and preparation science are covered in [RMA e-learning modules](https://regenmedacademy.com/e-courses/). Clinicians whose practice extends into aesthetic applications of adipose products can look at [aesthetic regenerative medicine coursework](https://regenmedacademy.com/cosmetic-courses/). Clinicians starting with PRP can begin with [the introductory PRP course](https://regenmedacademy.com/introduction-to-platelet-rich-plasma-prp-therapy-for-musculoskeletal-injuries/).

## **What should the patient hear before choosing?**

Here is how the consent conversation for this choice should run. Name all three options, say that each musculoskeletal use is off-label, and explain what the sources above found and where they stop, including the 2026 ACR guideline update. Walk through what each harvest involves, review the medication list with the prescriber, and give the cost of each option in writing. If your practice offers only one of the three, say so, and refer out for any procedure you do not perform.

## **Common pitfalls when comparing and marketing these modalities**

A few patterns drive most of the problems practices run into when they work across these three modalities.

The first is over-claiming superiority. Head-to-head RCT evidence is limited. Framing any single modality as “the best” or “the next generation” is both clinically inaccurate and a marketing overreach that regulators and plaintiff attorneys find easy to cite.

The second is conflating products. Using “stem cell therapy” as an umbrella label that covers PRP, BMAC, and adipose-based products is clinically imprecise, and FDA keeps these apart: its [consumer information on regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) (content current as of April 8, 2024) lists “stem cells,” “stromal vascular fraction (fat-derived cells),” and “ortho-biologics” separately among unapproved products. PRP is not stem cell therapy.

The third is over-promising regeneration. Describe these modalities by what they are, how they are regulated, and what named studies found, not by what they will do for a patient. Language that implies cartilage regrowth, tissue regeneration, or cure is not defensible and is not supported by the imaging and outcome data.

The fourth is offering enzymatic SVF as a clinical service. Two federal appellate courts have now rejected the legal arguments that underpin that offering. Clinicians who continue to offer SVF-based treatments outside an IND that is in effect are acting against both rulings and against FDA’s repeated notices that these products need an IND to be given legally. RMA does not teach SVF preparation.

The fifth is implying insurance coverage for MSK use of these products. Medicare’s national coverage determination for PRP covers certain chronic non-healing diabetic wounds and does not address musculoskeletal use, and commercial coverage depends on the plan. Do not advertise that insurance pays. Check each patient’s policy before you quote a price.

## **Frequently asked questions from clinicians**

**Is one modality definitively better than the others for knee osteoarthritis?**

No. A 2024 network meta-analysis of 48 studies found that HA and PRP improved pain compared with placebo, and that HA, PRP, and BMAC all improved function; PRP ranked near the top. A 2021 trial, only partly randomized, favored BMAC on most scores at 12 months, with a small PRP arm and no significant PRP-versus-HA difference. A 2019 retrospective review found no significant difference between MFAT and BMAC groups. The 2026 ACR guideline update strongly recommends against PRP and stem cell injections for knee and hip OA. Every one of these uses is off-label, and no modality has been shown to be definitively superior.

**How should we choose between BMAC and MFAT for one patient?**

The published evidence does not settle which suits which patient, so do not present one as the better match. Start with what each harvest asks of the patient and the team: BMAC needs a bone marrow draw and the skill for it, and MFAT needs a fat harvest under tumescent anesthesia and the skill for that. Review age, medical history, and every medication at intake, and follow your protocol and the prescriber on any hold. Then cover the off-label status, the evidence, and the cost in the consent conversation. RMA teaches adipose harvest; it does not teach bone marrow aspiration.

**Is SVF a legal option for in-clinic treatment?**

Not outside an investigational new drug application (IND) that is in effect. The FDA has classified enzymatically digested SVF as a drug, and two federal appellate courts have affirmed that position: the Eleventh Circuit in 2021 and the Ninth Circuit in 2024. Mechanically prepared SVF-like products are in a more ambiguous regulatory space, and the status of a specific mechanical method depends on its exact processing steps. Clinicians considering any SVF-related service should consult counsel and confirm the FDA framing for the specific system. RMA does not teach SVF preparation.

**What should we charge for each modality?**

Pricing should reflect fully loaded costs, local market, and positioning rather than a single national benchmark. The 2024 study by Tiao and colleagues, linked above, reported PRP prices at top U.S. orthopedic hospitals from three hundred fifty to two thousand eight hundred fifteen dollars per injection, with a median of eight hundred dollars. That is not a forecast for your practice, and this post cites no published range for BMAC or MFAT. Written pre-procedure pricing that includes every fee the patient will pay is both good consumer practice and useful compliance hygiene.

**How do we train a practice to offer all three?**

Plan on a progression. PRP is usually the entry modality because it is the least invasive and the lowest skill barrier. BMAC is typically added next, with structured training in bone aspiration technique, Hernigou zone anatomy, and concentration system operation. Adipose-based work is often the highest-barrier addition because it requires tumescent pharmacology, liposuction skill, processing competence, and particular attention to the regulatory boundary between MFAT and SVF. Whichever combination you build toward (RMA teaches the PRP and adipose techniques; we do not teach bone marrow aspiration or SVF preparation), favor programs that put you hands on with each technique under supervision rather than piecing skills together from lectures alone.

**How should we talk to patients who have already had an unsuccessful treatment elsewhere?**

Start by reviewing the prior workflow. Ask about the specific product, dose and preparation where known, imaging guidance at the injection site, medication use around the procedure, and post-procedure instructions. The evidence for these uses is not settled, so a gap in the prior workflow does not show that a second attempt would help. A candid conversation about what is known, what is uncertain, and what response factors look like helps the patient decide whether a second attempt with the same modality, a switch to a different modality, or a different path altogether is appropriate.

**Can we market these as “stem cell therapy”?**

No. Avoid “stem cell therapy” for PRP, BMAC, and MFAT alike. PRP contains no stem cells, and for BMAC and MFAT use the precise product name, such as “bone marrow aspirate concentrate” or “microfragmented adipose tissue,” and say the product is not FDA approved for the use. FDA’s consumer information on regenerative medicine therapies (content current as of April 8, 2024) says the only FDA-approved stem cell products are blood-forming stem cells derived from umbilical cord blood, for disorders that affect the production of blood. Some states with stem cell laws also require a notice in advertising; follow any that applies, starting from our [rules by state page](https://regenmedacademy.com/regenerative-medicine-laws-by-state/).

## **Key takeaways**

- PRP, BMAC, and adipose-derived products are three genuinely different modalities with different biology, different invasiveness, different cost structures, and different regulatory framing.
- PRP contains no stem cells. BMAC and MFAT contain mesenchymal-type cells at different densities. SVF is a drug per FDA and two federal appellate courts.
- All three are used off-label for musculoskeletal injection, and none is FDA approved to treat a musculoskeletal condition. Coverage depends on the plan, so check each patient’s policy before you quote a price.
- Head-to-head evidence is limited. A 2024 network meta-analysis found PRP improved pain and function compared with placebo, and BMAC function only; a 2019 retrospective review found no significant difference between MFAT and BMAC groups. The 2026 ACR guideline update strongly recommends against PRP and stem cell injections for knee and hip OA. No modality has been shown to be definitively superior.
- Match modality to indication and patient factors rather than fitting every patient to one tool.
- Training barriers rise from PRP to BMAC to adipose-based work, and full-modality practices need structured training across all three. RMA teaches PRP and adipose work; it does not teach bone marrow aspiration or SVF preparation, which need separate training.
- Avoid conflating products under the “stem cell therapy” label, avoid claims of cartilage regeneration, and avoid implying insurance coverage for MSK use.

## **RMA Disclosure**

Regenerative Medicine Academy (RMA) is an education company that provides clinician training in some of the techniques discussed in this article. This content is educational and does not constitute a claim of clinical superiority, a guarantee of outcomes, or a substitute for individual clinical judgment.

## **For clinicians ready to take the next step**

Clinicians evaluating a single-modality or multi-modality orthobiologic service line can explore hands-on procedural curricula, didactic foundations, and aesthetic-focused programs through RMA. The course catalog covers PRP and adipose-based techniques. RMA does not teach bone marrow aspiration or SVF preparation; BMAC and SVF are covered in this article so you can compare the three modalities and counsel patients accurately.

You can see how the PRP and adipose techniques are taught in [the RMA course catalog](https://regenmedacademy.com/our-courses/), from PRP fundamentals to [adipose and MFAT work](https://regenmedacademy.com/adipose-mfat-tissue-harvesting-course-hands-on-regenerative-medicine-training/). [Ask about dates and fit](https://regenmedacademy.com/contact/).

The course that goes with this post

## Musculoskeletal training

PRP and adipose training for joint, tendon and ligament work, in the order a practice adds them.

[See the course](https://regenmedacademy.com/musculoskeletal-courses/)

[Request a date now](https://regenmedacademy.com/contact/?course=prp)

[Or see all courses](https://regenmedacademy.com/our-courses/)

## Important information

### Education, not medical advice

Regen Med Academy provides education and training for licensed healthcare providers. Everything on this site is for educational purposes only. It is not medical advice, not a treatment recommendation, and not an offer to treat. Providers are responsible for practicing within the scope of their own license and their own state law.

### Where a course can run

Courses are taught only in states where the modality is legal for the license you hold. State law in this field changes, sometimes more than once a year. Our reading of each state, with its sources and the date we checked, is on the [rules by state page](/regenerative-medicine-laws-by-state/). It is a starting point, not legal advice. It is your responsibility to confirm the modality is legal in your state for your license. Do that before you book. The authority on your own scope is your licensing board, not us. State medical board contact details are published by the [Federation of State Medical Boards](https://www.fsmb.org/contact-a-state-medical-board/).

### Training on live patients

Procedures performed during training are performed on consenting patients, by licensed providers, under supervision. Participation is voluntary and outcomes vary.

### Products and modalities

Some products and modalities discussed in these courses are not FDA approved or cleared for the uses described. Regen Med Academy does not manufacture, sell or endorse any product, and does not approve or clear any product. The FDA publishes guidance for patients and providers on [regenerative medicine therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies).

### What a certificate is, and is not

Regen Med Academy does not offer CMEs, credit hours or accreditation of any kind. What you receive is a Certificate of Completion. It records that you attended and performed the procedures under supervision. It is not a license, not a board certification, and it does not expand your scope of practice.

### Coverage is yours to arrange

You are responsible for your own malpractice coverage. We will help you work out what to ask your carrier, and we recommend getting the answer in writing. Regen Med Academy does not provide, arrange or extend coverage to trainees, and nothing on this page is legal advice or an assurance of coverage.

[PrevPreviousAdipose tissue harvesting for regenerative medicine: techniques, applications, and training](https://regenmedacademy.com/adipose-tissue-harvesting-for-regen-medicine/)

[NextUltrasound-guided injection techniques in regenerative medicine: why training mattersNext](https://regenmedacademy.com/ultrasound-guided-injection-techniques/)

#### Table of Contents

Prefer our take? Star us in Google.

## More from the blog

[Nov 4, 2026By Oscar Tellez ### 351 or 361: which rule covers the product in my clinic? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/351-vs-361-hctp-rules/)[Nov 3, 2026By Oscar Tellez ### Who on my staff can draw, spin and inject PRP? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/who-can-draw-spin-and-inject-prp/)[Nov 2, 2026By Oscar Tellez ### How do I get trained in PRP injections as a nurse practitioner? Read Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education…](https://regenmedacademy.com/prp-training-for-nurse-practitioners/)

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/regenmedacademy.com\/#organization","name":"Regen Med Academy","sameAs":["https:\/\/www.facebook.com\/regenmedacademy\/","https:\/\/www.instagram.com\/regenmedacademy\/","https:\/\/www.linkedin.com\/company\/regenerative-medicine-academy-usa\/"],"logo":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/#logo","url":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","contentUrl":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/08\/rma-logo-short.png","caption":"Regen Med Academy","inLanguage":"en-US","width":"964","height":"160"}},{"@type":"WebSite","@id":"https:\/\/regenmedacademy.com\/#website","url":"https:\/\/regenmedacademy.com","name":"Regen Med Academy","alternateName":"Regenerative Medicine Academy","publisher":{"@id":"https:\/\/regenmedacademy.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-vs.-BMAC-vs.-adipose_-comparing-orthobiologic-treatment-options-r3.webp","url":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-vs.-BMAC-vs.-adipose_-comparing-orthobiologic-treatment-options-r3.webp","width":"1024","height":"1024","caption":"Three labeled syringes side by side comparing orthobiologic options: yellow PRP, reddish BMAC, and pale particulate adipose tissue","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/regenmedacademy.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/regenmedacademy.com\/our-blogs\/","name":"Blogs"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/regenmedacademy.com\/category\/adipose\/","name":"Adipose"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/","name":"PRP vs. BMAC vs. adipose: comparing orthobiologic treatment options"}}]},{"@type":"WebPage","@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#webpage","url":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/","name":"PRP Vs BMAC Vs Adipose: Comparing Orthobiologics","datePublished":"2026-06-19T07:54:00-04:00","dateModified":"2026-11-04T12:25:43-05:00","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-vs.-BMAC-vs.-adipose_-comparing-orthobiologic-treatment-options-r3.webp"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#breadcrumb"}},{"@type":"Person","@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez","url":"https:\/\/regenmedacademy.com\/oscar-tellez\/","image":{"@type":"ImageObject","@id":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","url":"https:\/\/regenmedacademy.com\/wp-content\/litespeed\/avatar\/b825d4341c372553b72ec46678d94981.jpg?ver=1790899329","caption":"Oscar Tellez","inLanguage":"en-US"},"sameAs":["https:\/\/regenmedacademy.com\/oscar-tellez\/"],"worksFor":{"@id":"https:\/\/regenmedacademy.com\/#organization"}},{"@type":"BlogPosting","headline":"PRP Vs BMAC Vs Adipose: Comparing Orthobiologics","keywords":"PRP vs BMAC vs adipose","datePublished":"2026-06-19T07:54:00-04:00","dateModified":"2026-11-04T12:25:43-05:00","articleSection":"Adipose, PRP","author":{"@id":"https:\/\/regenmedacademy.com\/oscar-tellez\/","name":"Oscar Tellez"},"publisher":{"@id":"https:\/\/regenmedacademy.com\/#organization"},"description":"How PRP, bone marrow aspirate concentrate and adipose derived preparations differ in source, processing, handling and the regulatory framing around them.","name":"PRP Vs BMAC Vs Adipose: Comparing Orthobiologics","@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#richSnippet","isPartOf":{"@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#webpage"},"image":{"@id":"https:\/\/regenmedacademy.com\/wp-content\/uploads\/2026\/09\/PRP-vs.-BMAC-vs.-adipose_-comparing-orthobiologic-treatment-options-r3.webp"},"inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#webpage"}}]},{"@context":"https:\/\/schema.org","@type":"FAQPage","@id":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/#faq","url":"https:\/\/regenmedacademy.com\/prp-vs-bmac-vs-adipose-comparing-treatments\/","mainEntity":[{"@type":"Question","name":"Is one modality definitively better than the others for knee osteoarthritis?","acceptedAnswer":{"@type":"Answer","text":"No. A 2024 network meta-analysis of 48 studies found that HA and PRP improved pain compared with placebo, and that HA, PRP, and BMAC all improved function; PRP ranked near the top. A 2021 trial, only partly randomized, favored BMAC on most scores at 12 months, with a small PRP arm and no significant PRP-versus-HA difference. A 2019 retrospective review found no significant difference between MFAT and BMAC groups. The 2026 ACR guideline update strongly recommends against PRP and stem cell injections for knee and hip OA. Every one of these uses is off-label, and no modality has been shown to be definitively superior."}},{"@type":"Question","name":"How should we choose between BMAC and MFAT for one patient?","acceptedAnswer":{"@type":"Answer","text":"The published evidence does not settle which suits which patient, so do not present one as the better match. Start with what each harvest asks of the patient and the team: BMAC needs a bone marrow draw and the skill for it, and MFAT needs a fat harvest under tumescent anesthesia and the skill for that. Review age, medical history, and every medication at intake, and follow your protocol and the prescriber on any hold. Then cover the off-label status, the evidence, and the cost in the consent conversation. RMA teaches adipose harvest; it does not teach bone marrow aspiration."}},{"@type":"Question","name":"Is SVF a legal option for in-clinic treatment?","acceptedAnswer":{"@type":"Answer","text":"Not outside an investigational new drug application (IND) that is in effect. The FDA has classified enzymatically digested SVF as a drug, and two federal appellate courts have affirmed that position: the Eleventh Circuit in 2021 and the Ninth Circuit in 2024. Mechanically prepared SVF-like products are in a more ambiguous regulatory space, and the status of a specific mechanical method depends on its exact processing steps. Clinicians considering any SVF-related service should consult counsel and confirm the FDA framing for the specific system. RMA does not teach SVF preparation."}},{"@type":"Question","name":"What should we charge for each modality?","acceptedAnswer":{"@type":"Answer","text":"Pricing should reflect fully loaded costs, local market, and positioning rather than a single national benchmark. The 2024 study by Tiao and colleagues, linked above, reported PRP prices at top U.S. orthopedic hospitals from three hundred fifty to two thousand eight hundred fifteen dollars per injection, with a median of eight hundred dollars. That is not a forecast for your practice, and this post cites no published range for BMAC or MFAT. Written pre-procedure pricing that includes every fee the patient will pay is both good consumer practice and useful compliance hygiene."}},{"@type":"Question","name":"How do we train a practice to offer all three?","acceptedAnswer":{"@type":"Answer","text":"Plan on a progression. PRP is usually the entry modality because it is the least invasive and the lowest skill barrier. BMAC is typically added next, with structured training in bone aspiration technique, Hernigou zone anatomy, and concentration system operation. Adipose-based work is often the highest-barrier addition because it requires tumescent pharmacology, liposuction skill, processing competence, and particular attention to the regulatory boundary between MFAT and SVF. Whichever combination you build toward (RMA teaches the PRP and adipose techniques; we do not teach bone marrow aspiration or SVF preparation), favor programs that put you hands on with each technique under supervision rather than piecing skills together from lectures alone."}},{"@type":"Question","name":"How should we talk to patients who have already had an unsuccessful treatment elsewhere?","acceptedAnswer":{"@type":"Answer","text":"Start by reviewing the prior workflow. Ask about the specific product, dose and preparation where known, imaging guidance at the injection site, medication use around the procedure, and post-procedure instructions. The evidence for these uses is not settled, so a gap in the prior workflow does not show that a second attempt would help. A candid conversation about what is known, what is uncertain, and what response factors look like helps the patient decide whether a second attempt with the same modality, a switch to a different modality, or a different path altogether is appropriate."}},{"@type":"Question","name":"Can we market these as \u201cstem cell therapy\u201d?","acceptedAnswer":{"@type":"Answer","text":"No. Avoid \u201cstem cell therapy\u201d for PRP, BMAC, and MFAT alike. PRP contains no stem cells, and for BMAC and MFAT use the precise product name, such as \u201cbone marrow aspirate concentrate\u201d or \u201cmicrofragmented adipose tissue,\u201d and say the product is not FDA approved for the use. FDA\u2019s consumer information on regenerative medicine therapies (content current as of April 8, 2024) says the only FDA-approved stem cell products are blood-forming stem cells derived from umbilical cord blood, for disorders that affect the production of blood. Some states with stem cell laws also require a notice in advertising; follow any that applies, starting from our rules by state page."}}]}]
```